Keruakous AR - Search Results

1

Identifying Candidates for Effective Utilization of Stored Autologous PBSCs in Salvage Transplantation for Multiple Myeloma: Who Benefits Most?

Keruakous AR, Walker L, Denlinger M, Mian MAH, Bradshaw D, Kota VK, Jillella AP. Keruakous AR, et al. Hematol Rep. 2024 Jul 12;16(3):479-486. doi: 10.3390/hematolrep16030046. Hematol Rep. 2024. PMID: 39051419 Free PMC article.

2

Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m² versus 140 mg/m².

Brown Z, Scott C, Zhang LF, Sadek R, Clarke A, Jillella A, Keruakous AR, Clemmons AB. Brown Z, et al. Among authors: keruakous ar. Clin Lymphoma Myeloma Leuk. 2024 Sep;24(9):642-647. doi: 10.1016/j.clml.2024.05.005. Epub 2024 May 7. Clin Lymphoma Myeloma Leuk. 2024. PMID: 38845275

3

Equity in oncology care: addressing disparities in cancer treatment in Georgia.

Keruakous AR, Akpan I, Chahin M, Kirolos A, Keruakous M. Keruakous AR, et al. Front Public Health. 2024 May 2;12:1381075. doi: 10.3389/fpubh.2024.1381075. eCollection 2024. Front Public Health. 2024. PMID: 38756877 Free PMC article.

4

Barriers driving health care disparities in utilization of age-appropriate screening.

Keruakous AR, Soror N, Jiménez S, Ashley R, Keruakous M, Sadek BT. Keruakous AR, et al. Front Public Health. 2023 Mar 3;11:1100466. doi: 10.3389/fpubh.2023.1100466. eCollection 2023. Front Public Health. 2023. PMID: 36935668 Free PMC article. No abstract available.

5

Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.

Keruakous AR, Holter-Chakrabarty J, Schmidt SA, Khawandanah MO, Selby G, Yuen C. Keruakous AR, et al. Hematol Oncol Stem Cell Ther. 2023 Jan 12;16(1):52-60. doi: 10.1016/j.hemonc.2021.03.001. Hematol Oncol Stem Cell Ther. 2023. PMID: 36634281 Free article.

6

Clinical Considerations for Immunoparesis in Multiple Myeloma.

Chahin M, Branham Z, Fox A, Leurinda C, Keruakous AR. Chahin M, et al. Among authors: keruakous ar. Cancers (Basel). 2022 May 3;14(9):2278. doi: 10.3390/cancers14092278. Cancers (Basel). 2022. PMID: 35565407 Free PMC article. Review.

7

Prognostic impact of natural killer cell recovery on minimal residual disease after autologous stem cell transplantation in multiple myeloma.

Keruakous AR, Asch A, Aljumaily R, Zhao D, Yuen C. Keruakous AR, et al. Transpl Immunol. 2022 Apr;71:101544. doi: 10.1016/j.trim.2022.101544. Epub 2022 Jan 31. Transpl Immunol. 2022. PMID: 35093506 Free PMC article.

8

Research Staff Perspectives on Cancer Clinical Trials and Barriers to Recruitment: A Qualitative Research.

Keruakous AR, Day S, Garcia-Ramiu K, Yarbrough M, Asch AS. Keruakous AR, et al. Cureus. 2021 Aug 15;13(8):e17202. doi: 10.7759/cureus.17202. eCollection 2021 Aug. Cureus. 2021. PMID: 34540430 Free PMC article.

9

Genomic profiling is a supplemental diagnostic and therapeutic modality for hairy cell leukemia variant.

Keruakous AR, Balakrishna P, Schmidt SA, Autry MT, Asch A. Keruakous AR, et al. Ann Hematol. 2021 Jun;100(6):1629-1630. doi: 10.1007/s00277-021-04408-z. Epub 2021 Jan 12. Ann Hematol. 2021. PMID: 33433650 No abstract available.

10

Is a higher boost dose of radiation necessary after breast-conserving therapy for patients with breast cancer with final close or positive margins?

Sadek BT, Homayounfar G, Abi Raad RF, Niemierko A, Shenouda MN, Keruakous AR, Specht MC, Taghian AG. Sadek BT, et al. Among authors: keruakous ar. Breast Cancer Res Treat. 2015 Nov;154(1):71-9. doi: 10.1007/s10549-015-3579-9. Epub 2015 Sep 29. Breast Cancer Res Treat. 2015. PMID: 26420403

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters